martedì, 27 luglio 2021
29 Novembre 2016

EC Approves Nivolumab for Hodgkin Lymphoma

The European Commission (EC) has approved nivolumab (Opdivo) for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin (Adcetris), according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor. The approval was based on an objective response rate (ORR) of 66% (95% CI, 56-76; n = 63) in a combined analysis of 95 patients with … (leggi tutto)